Status: Recruiting
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).
Participants needed: 51
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSUpdated: Sep 19, 2024Locations: 1
Eligibility criteria
Patients must have histologically confirmed stage IV Head&Neck Squamous Cell Car... [+16]
Patients with residual disease after surgery. Marginal resection of any lesion i... [+10]